and HE proteins and as a result hepatic preparations from such animals are more efficient in activating chemical carcinogens relying on these proteins for their activation 181. It appears that it is the hyperketonaemia that accompanies diabetes that is responsible, at least partly, for these effects [Y] .
tliirnati 1'450 I fumily A s far as the possible role of the P4SO I family in human cancer is concerned, the questions that arise are whether this family is present in human tissues, whether it is inducible, and whether its substrate specificity is similar to that characterizing the orthologous proteins isolated from laboratory animals. Immunologically, the P450 I proteins have been detected in human hepatic microsomes and marked interindividual variations wcrc noted, indicating the possibility of polymorphism. T h e P450 1 activity is higher, at least in the liver and placenta, in smokers when compared with nonsmokers, suggesting enzyme induction. T h e induced proteins appear to readily metabolize benzo[ u Ipyrene and ethoxyresorufin. two substrates closely associated with P450 1A 1 activity.
~'otic~hi.sioti.s
Two fundamental requirements are necessary for a chemical t o exhibit carcinogenicity in an animal species. First, the chemical must have the potential to be metabolically converted to genotoxic intermediates and secondly, the animal species must possess the enzyme system( s) that catalyse these activation pathways. Since these enzyme systems are present at very low levels in animals, the ability of a chemical t o induce their synthesis may be a critical factor in determining its carcinogenic potential. These include the fact that enzymic reactions arc generally clean and involve rathcr mild reaction conditions and they introduce a large rate acceleration for a reaction. Most important is the high level of chcmoselectivity associated with an enzyme catalysed reaction, including stcreoselectivity and enantioselectivity. With advances in molecular biology, the construction of 'designer enzymes' may be anticipated, i.e. proteins restructured by genetic engineering to introduce more efficient and selective active-site geometry.
T h e cytochromes 1 ' 4 5 0 ideally fit these requirements, since they, as a group, catalyse the hydroxylation of alkanes and aromatic compounds, thc cpoxidation of polyunsaturated fatty acids, and the N-and 0-dealkylation of secondary and tertiary amincs. to name but a few examples. However, there are some basic problems to be solved before plunging headlong into the commercial application of the cytochromcs 1'-450. First, they generally function by using reduced pyridine nucleotides as the source of reducing equivalcnts needed for the reduction o f the haem iron. Thcsc reducing equivalents aIc transferrcd by way of an FMN-FAD-containing flavoprotein (wirh microsomal types of cytochromes 1 ' 4 5 0 ) o r an abbreviated electron transfer chain composed o f a flavoprotcin and an iron-sulphur protein (with mitochondria1 types of cytochromcs P-450 ). When considering the industrial application of cytochrome 1 ' 4 5 0 , one must first recognize that electrons are cxpensivc. This includes the conventional method o f adding the required pyridine nucleotidc with a rcgcncrating system. Thus. the successful use of cytochromes 1 ' 4 5 0 will require the development of alternative means of clelivcring electrons t o the haemoprotein, either in the form o f light-activated reduction systems, refined clectrochcmical processes o r thc usc of inexpensive alternatives. such as peroxide-driven reactions using an abundant and cheap rcagcnt such as tertiary butyl hydropcroxide. Thcsc techniques, although they may solve the problem of the economics o f electrons, undoubtedly will introduce new uncertainties -notably the stability o f key intermediates, such as the oxy-form of the cytochrome /'-450-substrate complex. This essential intermcdiatc has : I propensity for decomposing, thereby releasing reactive species of oxygen, such as hydroxyl radicals or superoxide which can destroy the hacm of the haemoprotein.
Central t o thc use of enzymes for industrial speciality chemical synthesis, is the need t o stabilizc the protein t o extend its useful life as a catalyst. Techniques of protein cngineering can be applied t o increase the number of saltbridges in the protein molecule; t o enhance the number of hydrogen bonds in the molecule or to facilitate thc number of aromatic-aromatic amino acid interactions. Many of these techniques remain t o be tried (however. one really needs t o know the three-dimensional structure o f the protein before attempting such changes). Also, the enzyme can be immobi-lizcd on to a support platform; entrapped in a gel or permeable fibre, or be encapsulatcd into a membrane system together with its cofactors. When considering all these possibilities, combined with the recognized instability of purified cytochromes 1'-450, the conclusion to use cells that have been transformed to express specific cytochromes 1'-450 seems the most viable short-term alternative.
A major consideration when contemplating the use of the cytochromes 1J-450 for industrial purposes, is the need to master the limitation of kinetics imposed by the prcscnce of the organic-aqueous interface which would be present during large-scale conversion proccsses. The cytochromes 1'-450 function in an aqueous environment, while the organic chcmical substrates are generally hydrophobic. Howevcr, these differences in solubility may be used to advantage, since it could reduce thc cost o f concentrating and purifying desired products that would accumulate in the organic phasc of the reaction system. Many unknowns remain t o be conquered as one ventures into thc application of enzymes t o industrial processes, but these merely add cxcitcmcnt to the challenge. 'There are a bewildering array of substrates that are oxidatively metabolized by the different cytochromes P450.
Likewise. thcrc is an cvcr increasing inventory of cytochromes 1'-450 under study. These have been classified into families as shown in Fig. 1 121. Nearly 100 diffcrcnt cytochromes 1'-450s have been cloned and sequenced [3] and ccrtainly hundreds more remain to be examined. Thus, what was once ii dream is now onc step closer to reality. We stand o n the threshold o f the day when 'dcsigncr' cytochromes P 4 S O will exist and will be used for new types of chemical prbccsscs. Expression systems arc now available which allow the production of significant quantitics of spccific cytochromes 1'-450. Thcse can be applied to study thc role of individual human cytochromcs 1J-450 in toxic reactions or for the dctoxication of xenobiotics. The grcatcst promise exists for their commercial application t o chemical processes o f pollution control, modification of undesirable chemicals in food o r the synthesis o f new pharmaceuticals. Fulfilment of these promises for the applied chemical and medical scicnce await those bold enough to take advantagc o f this opportunity.
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